Under a tenth of individuals that would benefit from weight-loss injections including Wegovy are able to get them, states the WHO as it publishes its first advice on the therapies.
Given in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is urging more widespread and fairer availability to these injectable treatments.
Per estimates, more than two billion will be obese by 2030 without intervention.
"Our new guidelines acknowledges that obesity is a chronic disease that can be treated with comprehensive and lifelong support," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are key barriers to widespread access to the jabs that can aid individuals in losing substantial body mass, says the agency.
Weight-Loss Drug Supply Crisis
Even in the present most optimistic case, the supply of these medications would only suffice for around 100 million people – under 10% of the global need, as stated by the WHO.
The recommendation calls on nations and manufacturers to increase availability, via strategies like voluntary licensing.
The intellectual property rights on the active ingredient – the primary component of a leading brand – is due to expire in a number of nations in 2026.
The Way Obesity Drugs Function
These medications replicate a body's own hormone to slow digestion, curb appetite and boost feelings of fullness so people eat less.
Patients typically start to lose weight in the initial weeks of beginning the once-weekly jabs.
Studies indicates users may put most of the weight back on after a year of halting the medication, when their usual food cravings return.
Being carrying excess weight increases your chance for developing medical conditions, such as type 2 diabetes, heart disease, stroke, and certain malignancies.
Excess weight impacts people in all nations and was linked to 3.7 million deaths worldwide in 2024, as per the health agency.
